| Literature DB >> 29223614 |
Jae-Hoon Ko1, Hyeri Seok1, Ga Eun Park1, Ji Yeon Lee1, Ji Yong Lee1, Sun Young Cho1, Young Eun Ha1, Ji-Man Kang2, Yae-Jean Kim2, Cheol-In Kang1, Doo Ryeon Chung1, Jae-Hoon Song1, Kyong Ran Peck3.
Abstract
To evaluate host susceptibility factors to Middle East respiratory syndrome coronavirus (MERS-CoV) infection, we conducted a retrospective cohort study from the single largest exposure event of the 2015 Korean MERS outbreak. A total of 175 patients were closely exposed to a super-spreader, 26 of which were infected (14.9%). In a multivariate analysis, history of autologous stem cell transplantation (HR, 31.151; 95% CI, 5.447-178.145; P < 0.001) and tachypnea at ED (HR, 4.392; 95% CI, 1.402-13.761; P = 0.011) were significantly associated with MERS-CoV infection.Entities:
Keywords: Middle East respiratory syndrome coronavirus; Stem cell transplantation; Susceptibility; Tachypnea
Mesh:
Year: 2017 PMID: 29223614 PMCID: PMC7129617 DOI: 10.1016/j.jiac.2017.09.008
Source DB: PubMed Journal: J Infect Chemother ISSN: 1341-321X Impact factor: 2.211
Baseline characteristics and clinical presentation of the study population at ED visit.
| Variables | Infected with MERS (n = 26) | Not infected with MERS (n = 149) | |
|---|---|---|---|
| Demographics | |||
| Age, years (mean ± SD) | 56.5 ± 16.8 | 52.2 ± 19.9 | 0.306 |
| Male sex | 13 (50%) | 61 (40.9%) | 0.388 |
| BMI (kg/m2, median, IQR) | 22.0 (19.8–24.4) | 22.1 (19.8–24.1) | 0.992 |
| Exposure sites | |||
| Radiology or registration | 3 (11.5%) | 55 (36.9%) | 0.011 |
| Zone II | 13 (50.0%) | 44 (29.5%) | 0.040 |
| Zone III | 7 (26.9%) | 15 (10.1%) | 0.026 |
| Zone IV | 3 (11.5%) | 35 (23.5%) | 0.173 |
| Immunosuppressive therapies | |||
| Chemotherapy | 3 (11.5%) | 36 (24.2%) | 0.154 |
| Radiotherapy | 1 (3.8%) | 9 (6.0%) | 1.000 |
| Steroid use | 1 (3.8%) | 2 (1.3%) | 0.385 |
| Underlying diseases | |||
| Hypertension | 12 (46.2%) | 38 (25.5%) | 0.031 |
| Diabetes mellitus | 4 (15.4%) | 25 (16.8%) | 1.000 |
| Cardiovascular diseases | 9 (34.6%) | 21 (14.1%) | 0.020 |
| Pulmonary diseases | 1 (3.8%) | 4 (2.7%) | 0.557 |
| Liver diseases | 1 (3.8%) | 6 (4.0%) | 1.000 |
| Renal diseases | 2 (7.7%) | 3 (2.0%) | 0.160 |
| Solid cancers | 9 (34.6%) | 58 (38.9%) | 0.676 |
| Hematologic diseases | 3 (11.5%) | 9 (6.0%) | 0.391 |
| Autologous SCT | 2 (7.7%) | 1 (0.7%) | 0.058 |
| Solid organ transplantation | 0 (0.0%) | 3 (2.0%) | 1.000 |
| Charlson's WIC (median, IQR) | 2 (1–6) | 2 (0–6) | 0.444 |
| Vital signs (median, IQR) | |||
| Fever (>38 °C) | 6 (23.1%) | 20 (13.4%) | 0.231 |
| Hypotension (MAP < 65) | 0 (0.0%) | 7 (4.7%) | 0.596 |
| Tachycardia (HR > 90) | 11 (42.3%) | 44 (29.5%) | 0.195 |
| Tachypnea (RR > 24) | 4 (15.4%) | 4 (2.7%) | 0.018 |
| SIRS | 7 (26.9%) | 36 (24.2%) | 0.763 |
| Concomitant infections | 10 (38.5%) | 45 (32.8%) | 0.652 |
| Bacterial | 8 (30.8%) | 53 (35.8%) | 0.795 |
| Tuberculosis | 1 (3.8%) | 1 (0.7%) | 0.276 |
| Viral | 1 (3.8%) | 7 (4.7%) | 1.000 |
Data are expressed as the number (%) of patients, unless indicated otherwise.
Abbreviations: MERS, Middle East respiratory syndrome; SD, standard deviation; BMI, body mass index; IQR, interquartile range; SCT, stem cell transplantation; WIC, weighted index of comorbidity.
Multivariate analysis for host susceptibility factors to MERS-CoV infection.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Exposure sites | ||||
| Radiology or registration area | 1 | 1 | ||
| Zone II | 4.711 (1.342–16.535) | 0.016 | 5.990 (1.503–23.867) | 0.011 |
| Zone III | 7.413 (1.916–28.686) | 0.004 | 5.520 (1.199–25.411) | 0.028 |
| Zone IV | 1.531 (0.309–7.587) | 0.602 | 1.313 (0.263–6.550) | 0.740 |
| Autologous SCT | 6.181 (1.458–26.200) | 0.013 | 31.151 (5.447–178.145) | <0.001 |
| Tachypnea | 6.535 (2.243–19.037) | 0.001 | 4.392 (1.402–13.761) | 0.011 |
| Hypertension | 2.283 (1.056–4.937) | 0.036 | 1.872 (0.746–4.698) | 0.181 |
| Cardiovascular diseases | 2.788 (1.242–6.257) | 0.013 | 2.004 (0.762–5.270) | 0.159 |
Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; SCT, stem cell transplantation.